BrainStorm Cell (NASDAQ: BCLI) director receives 200,000 RSUs as stock award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

FRENKEL JACOB A reported acquisition or exercise transactions in this Form 4 filing.

BrainStorm Cell Therapeutics director Jacob A. Frenkel received a grant of 200,000 shares of Common Stock in the form of restricted stock units. The award was made at a stated price of $0.00 per share as stock-based compensation, rather than an open-market purchase.

According to the grant terms, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six-month anniversary of that date, if he remains employed by the company. After this award, Frenkel directly holds 243,777 shares of the company’s stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FRENKEL JACOB A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	200,000	$0.00	--

Holdings After Transaction: Common Stock — 243,777 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 200,000 shares Grant price: $0.00 per share Holdings after transaction: 243,777 shares +2 more

5 metrics

RSUs granted 200,000 shares Restricted stock unit award to director on February 26, 2026

Grant price $0.00 per share Stated price for RSU award

Holdings after transaction 243,777 shares Director’s direct ownership following RSU grant

Initial vesting 50% of award Vests on grant date, subject to employment

Second vesting 50% of award Vests six months after grant, subject to employment

Key Terms

restricted stock units ("RSUs"), 2014 Global Share Option Plan, vesting, Form 4, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vesting financial

"The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/29/2026 - 05:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRENKEL JACOB A

(Last)

(First)

(Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		200,000⁽¹⁾	A	$0.00	243,777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Jacob A. Frenkel	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did BRAINSTORM CELL THERAPEUTICS (BCLI) disclose about Jacob A. Frenkel?

The company reported that director Jacob A. Frenkel received 200,000 restricted stock units as stock-based compensation. The grant was made at a stated price of $0.00 per share and increased his direct holdings to 243,777 shares of BrainStorm Cell Therapeutics common stock.

How many BrainStorm Cell Therapeutics (BCLI) shares were granted to Jacob A. Frenkel?

Jacob A. Frenkel was granted 200,000 shares of BrainStorm Cell Therapeutics common stock in the form of restricted stock units. This compensation-related award was recorded at a price of $0.00 per share and represents a significant portion of his total reported direct holdings.

How do Jacob A. Frenkel’s RSUs in BCLI vest over time?

Frenkel’s 200,000 BrainStorm Cell Therapeutics restricted stock units vest in two equal installments. Half of the award vests on the grant date, and the remaining half vests on the six-month anniversary, contingent on his continued employment with the company through each applicable vesting date.

What is Jacob A. Frenkel’s total BCLI shareholding after this Form 4 transaction?

Following the award, Jacob A. Frenkel directly holds 243,777 shares of BrainStorm Cell Therapeutics common stock. This figure includes the 200,000 restricted stock units granted under the company’s 2014 Global Share Option Plan, as reported in the insider transaction disclosure.

Was Jacob A. Frenkel’s BCLI transaction a market purchase or a compensation grant?

The transaction was a compensation-related grant, not a market purchase. BrainStorm Cell Therapeutics reported that the 200,000 shares were awarded as restricted stock units at a stated price of $0.00 per share under the company’s 2014 Global Share Option Plan.

Under which plan were Jacob A. Frenkel’s BCLI RSUs granted?

The 200,000 restricted stock units granted to Jacob A. Frenkel were awarded under BrainStorm Cell Therapeutics’ 2014 Global Share Option Plan. The footnote explains the RSUs’ vesting schedule and the employment condition tied to each vesting date.